gene therapy

Another gene therapy name is likely to be sold, with ASTELLAS PHARMA/ADR (OTC: ALPMY) announcing a trans-continental buyout deal late Monday. Hefty Premium For Audentes  Astellas and Audentes Therapeutics Inc (NASDAQ: BOLD) said they have entered a definitive agreement for the...

Abeona Therapeutics Inc (NASDAQ: ABEO)'s market capitalization was growing by about two-thirds Tuesday following an announcement concerning the exploration of strategic options. The thinly traded micro-cap cell and gene therapy company said it has initiated a review of strategic options in...

KeyBanc Capital Market's bull case for Catalent Inc (NYSE: CTLT) has come to an end. The company has taken the necessary steps to gain exposure to the high-growth biologics and gene therapy space, according to the sell-side firm.  The Analyst Donald Hooker downgraded Catalent from...

Gene therapy is an emerging field of drug development. From large-cap pharma to tiny biotechs, many companies are trying to make a name for themselves in gene therapy — a novel approach to treating or preventing diseases using genes. Spark Therapeutics Inc (NASDAQ: ONCE)'s...

Shares of Mustang Bio Inc (NASDAQ: MBIO) are skyrocketing to their highest level in about a year Thursday morning. What Happened The microcap biotech that develops next-gen cell and gene therapies for hematologic cancers, glioblastoma and rare genetic diseases announced Wednesday after the market...

Fibrocell Science Inc (NASDAQ: FCSC) is one of Monday's biggest gainers after the cell and gene therapy company focused on diseases of skin and connective tissue announced a collaboration agreement to develop its gene therapy candidate. What Happened The nanocap biotech said Monday it...

Gene therapy deal news continues to trickle in after Catalent Inc (NYSE: CTLT) announced an agreement to buy another gene and cell therapy CDMO. Catalent, which provides technologies and integrated solutions for biologic and biosimilar development, said it has entered into a definitive agreement to...

Biogen Inc (NASDAQ: BIIB) to acquire gene therapy company Nightstar Therapeutics PLC (NASDAQ: NITE). Roche Holdings AG Basel ADR (OTC: RHHBY) agrees to buy Spark Therapeutics Inc (NASDAQ: ONCE). Sarepta Therapeutics Inc (NASDAQ: SRPT) exercises option to buy Myonexus Therapeutics for $165...

Smaller gene therapy biotechs are taking the spotlight given the M&A interest surrounding them. One such gene therapy company saw its shares rallying by more than 30 percent Monday following the release of clinical trial results for two of its gene therapies. What Happened...

Biogen Inc (NASDAQ: BIIB) is the latest biotech company to jump onto the gene therapy bandwagon. What To Know Biogen, which focuses on developing therapies for neurological and neurodegenerative diseases, has agreed to acquire U.K.-based gene therapy company Nightstar Therapeutics PLC (NASDAQ: NITE...

The bullish case for Applied Genetic Technologies Corp (NASDAQ: AGTC), a nano-cap biotech conducting human clinical trials of adeno-associated virus-based gene therapies, can be made on the basis of an encouraging pipeline and valuation reasons, according to Wells Fargo. The Analyst Wells Fargo...

Uniqure NV (NASDAQ: QURE), a gene therapy company that focuses on severe unmet medical needs, could "dominate" the space with its AMT-061 therapy, according to B. Riley FBR. The Analyst B. Riley FBR's Madhu Kumar initiated coverage of Uniqure with a Buy rating and $50 price target....

Shares of bluebird bio Inc (NASDAQ: BLUE) — a clinical-stage biopharmaceutical company focused on bringing to market advanced products based on the potential of gene therapy — have been highly volatile, but the company has a "clear path" toward commercialization,...

Spark Therapeutics Inc (NASDAQ: ONCE) saw its name transition from Wall Street headlines to Main Street headlines after a U.S. Food and Drug Administration voted favorably on the company's therapy. Spark develops a gene therapy treatment called Luxturna for a rare inherited blindness disease,...

Shares of GenVec Inc (NASDAQ: GNVC) are set to record 200-percent gains after signing an option deal last week with Washington University in St. Louis. The option deal is to license intellectual property and technology related to gene editing and pulmonary endothelial cell targeting. The deal also...